Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzastaurin (ENGAGE) in Newly Diagnosed DGM1+ Glioblastoma
NCT03776071Phase 3Completed
- Sponsor
- Denovo Biopharma
- Start
- Dec 2020
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of enzastaurin in glioblastoma (GBM), sponsored by Denovo Biopharma. Started Dec 2020; status: completed.
02
Drugs
enzastaurin
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03776071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03776071.